Castle Biosciences, Inc. Stock News

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present a company overview at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 3:00 p.m. ET.

On Friday, the commercial-stage diagnostics company, Castle Biosciences (CSTL), announced new data to claim that its gene expression profile test, DecisionDx-Melanoma, performed better…

Wasatch Global Investors, an investment management firm, published its "Wasatch Micro Cap Fund" fourth quarter 2021 investor letter – a copy of which can be downloaded here.

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Castle Biosciences press release (CSTL): Q4 GAAP EPS of -$0.25 beats by $0.23.Revenue of $25M (+44.5% Y/Y) beats by $0.85M.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2021.

Castle Biosciences, Inc.'s (CSTL) CEO Derek Maetzold on Q4 2021 Results - Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.48 (-108.7% Y/Y) and…

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PALM BEACH, FL , Feb. 18, 2022 /PRNewswire/ -- PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few years. Countries are racing to slow down the spread of the disease by implementing necessary measures and increasing sample testing. The growing demand for COVID-19 diagnostic procedures and products alone has created immense opportunities in the healthcare industry, thus augmenting the market value. According to Fortune Business Insights: "The PCR technique segment dominated the market in 2020. The dominance is attributable to the increased quantification of patent samples by the use of PCR. PCR adoption has also contributed to the considerable growth of the segment. Moreover, the launch of new PCR-based detection techniques is like to surge the demand of for PCR instruments in the upcoming years." For example, the emergence of the COVID-19 pandemic has led to an explosion of research on various combinations of compounds in laboratories to develop COVID-19 diagnostics and therapies.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

Related Stocks: PING , RLJ , DEA , CSGS , ABBV , HRTX , AVGOP.PFD , WFCPL.PFD , CSTL , DHRPA.PFD , BACPL.PFD , VERX , COR , VNT , LRCX , APLS , SEDG , Z ,